Research Article

Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds

Yssel Mendoza Marí, 1 Maday Fernández Mayola, 1 Ana Aguilera Barreto, 2 Ariana García Ojalvo, 1 Yilian Bermúdez Alvarez, 2 Ana Janet Mir Benítez, 3 and Jorge Berlanga Acosta 1

1 Wound Healing and Cytoprotection Group, Biomedical Research Direction, Center for Genetic Engineering and Biotechnology, Avenue 31/158 and 190, P.O. Box 6162, Playa, 10600 Havana, Cuba
2 Formulation Department, Technological Development Direction, Center for Genetic Engineering and Biotechnology, Avenue 31/158 and 190, P.O. Box 6162, Playa, 10600 Havana, Cuba
3 Esthetic Surgery Department, "Joaquín Albarrán" Hospital, Avenue 26 and Boyeros, Plaza de la Revolución, 10600 Havana, Cuba

Correspondence should be addressed to Yssel Mendoza Marí; yssel.mendoza@cigb.edu.cu

Received 20 January 2016; Accepted 28 March 2016

Academic Editor: Selahattin Özmen

Copyright © 2016 Yssel Mendoza Marí et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In addition to its cytoprotective effects, growth hormone-releasing peptide 6 (GHRP-6) proved to reduce liver fibrotic induration. CD36 as one of the GHRP-6 receptors appears abundantly represented in cutaneous wounds granulation tissue. The healing response in a scenario of CD36 agonistic stimulation had not been previously investigated. Excisional full-thickness wounds (6 mmØ) were created in the dorsum of Wistar rats and topically treated twice a day for 5 days. The universal model of rabbit's ears hypertrophic scars was implemented and the animals were treated daily for 30 days. Treatments for both species were based on a CMC jelly composition containing GHRP-6 400 μg/mL. Wounds response characterization included closure dynamic, RT-PCR transcriptional profile, histology, and histomorphometric procedures. The rat experiment indicated that GHRP-6 pharmacodynamics involves attenuation of immunoinflammatory mediators, their effector cells, and the reduction of the expression of fibrotic cytokines. Importantly, in the hypertrophic scars rabbit's model, GHRP-6 intervention dramatically reduced the onset of exuberant scars by activating PPARγ and reducing the expression of fibrogenic cytokines. GHRP-6 showed no effect on the reversion of consolidated lesions. This evidence supports the notion that CD36 is an active and pharmacologically approachable receptor to attenuate wound inflammation and accelerate its closure so as to improve wound esthetic.

1. Introduction

Hypertrophic scarring is a form of abnormal, exuberant healing, locally aggressive, and recurrent cutaneous fibroproliferative condition, characterized by excessive extracellular matrix (ECM) accumulation during the cutaneous healing process. Including keloids and hypertrophic scars (HTS), these aberrant processes lead to esthetically disfiguring scars, patients’ psychological stress, and functional impairment [1]. The cellular and molecular mechanisms underlying the formation of these raised dermal scars are poorly understood. Recent whole genome profiling and proteomic studies have led to the identification of regulatory elements with different expression profiles in HTS and keloid tissues [2]. The limited understanding of the pathophysiology of these processes has led to investigating a broad spectrum of potential antihypertrophic scarring candidates [3].

Triamcinolone acetonide (TA) has long been the steroid of choice for the treatment of skin fibrotic disorders, providing the best relief of local symptoms such as scars flattening. Nevertheless, TA is associated with adverse events such as dermal atrophy, telangiectasia, and immunosuppression [4, 5]. Despite the multitude of therapeutic strategies to prevent or reduce keloid and HTS formation, these conditions remain as orphan clinical niches of ultimately effective interventions [6].
Our group recently demonstrated the antifibrotic effects of the growth hormone-releasing peptide 6 (GHRP-6) in a rat model of liver cirrhosis. GHRP-6 prevented parenchymal fibrotic induration in more than 85% and removed in about 75% the accumulated fibrotic material in both preventive and therapeutic administration schemes. Differentially expressed genes in a microarray experiment indicated that GHRP-6 modulates the expression of genes involved in the redox metabolism, as in the mesenchymal cells response to injury [7].

During the last 15 years, a plethora of experimental evidence supports the pharmacological benefits of the exogenous administration of synthetic growth hormone-releasing peptides (GHRPs). In parallel to their growth hormone-releasing action, these agents exert cytoprotective effects encompassing cardiac and extracardiac organs [8]. GHRP-6 is a class of peptidyl GH secretagogue, similar to met-enkephalin, that has reproducibly shown antinecrogenic and antiapoptotic properties in multiple experimental scenarios, including ischemia/reperfusion [9–11]. Globally speaking, exogenously administered GHRP-6 has broadly been shown to act as a prosurvival factor for cells and tissues threatened by otherwise lethal insults.

More than a decade ago, CD36 was identified as one of the GHRP-6 receptors [12]. This is a scavenger receptor endowed with multiligand and multifunctional capabilities and is expressed by a broad constellation of mammalian cells [13]. Granulation tissue neovascularization is endowed with multiligand and multifunctional capabilities and is expressed by a broad constellation of mammalian cells [13]. Granulation tissue neovascularization is abundant in clinical samples of granulation tissue of either acute (deep burn injuries) or chronic (pressure ulcers) wounds, as in laboratory rat's controlled full-thickness wounds. This finding incited us to speculate on the effects associated with CD36 agonistic stimulation beyond the physiological role of CD36 in wound healing [14]. Serendipitous observations of our laboratory indicated that CD36 mRNA transcript appeared abundantly represented in clinical samples of granulation tissue during ischemic/reperfusion induction. The other hemisection was fixed in 10% buffered formalin, paraffin embedded, and 5-μm sectioned. The specimens were stained with hematoxylin/eosin (H/E) and Mallory trichrome to examine collagen deposit. Other slides were destined for immunohistochemistry (as described below).

The impact of the treatment on the neodermal matrix reconstitution was qualitatively graded as described [17, 18]:

- Immature granulation tissue with a null or incipient formation of collagen fibrils, focally distributed with no alignment and not organized meshwork. Fibrin material prevails in the field. Mallory staining is detected in scarce foci.

- Scarc collagen fibrils suggestive of a primitive degree of organization, focally distributed, without horizontal alignment along the wound bed. Yet, fibrin occupies more than 50% of the field. Limited number of primitive neoformed vessels with empty lumen. Relative increase of positivity to Mallory staining.

- A general but coarse image of ECM granulation tissue accumulation, containing intermixed vertically and horizontally oriented collagen fibrils. Full replacement of fibrin by collagen. Fibrin has been fully replaced by collagen. Affinity to Mallory staining is observed.

- Complete ECM reconstitution, with mature and finely organized collagen fibrils horizontally deposited in the neodermis. The whole matrix appears positive to Mallory staining.

2. Materials and Methods

2.1. Ethics. The experiments were conducted following the approval by the institutional Animal Welfare Committee. All the procedures were conducted following the internal standards of animal care and protection established by the Animal Facility Core of the Center for Genetic Engineering and Biotechnology, Havana, Cuba.

2.2. GHRP-6 Formulation and Treatments. The hexapeptide GHRP-6 (His-d-Trp-Ala-Trp-d-Phe-Lys-NH2) was purchased from BCN Peptides (Barcelona, Spain). Fresh preparations were obtained by diluting the peptide in sterile 1% sodium carboxymethylcellulose (CMC-) based jelly formulation to a final concentration of 400 μg/mL.
The number of infiltrating immunoinflammatory cells and neoformed vessels was determined within the granulation tissue of each wound. For this purpose, images of at least 10 microscopic fields (10–20x magnification) were captured and photographed so that mature vascular structures and infiltrated mononuclear cells were counted along with the assistance of the ImageJ processing system, version 1.46r.

2.4. CD31 Immunohistochemistry. Immunohistochemical determination of CD31 expression (platelet endothelial cell adhesion molecule-1, PECAM-1) was conducted as this is a marker protein of mature vascular endothelium [19]. Sections (5 μm) were mounted on chromium-coated slides, dewaxed, rehydrated, rinsed, and washed in PBS 1x solution for 30 min. Once endogenous peroxidase was quenched, the specimens were treated with target retrieval solution (Dako) equilibrated at 99°C. Tissue samples were then incubated for 40 min with 1/50 dilution of anti-CD31 antibody (Abcam 28364, USA) in background reducing solution (Dako). The immunohistochemical reactions were carried out using the labelled streptavidin/biotin-horseradish peroxidase conjugate method, according to the manufacturer's instructions (Dako). The peroxidase reaction was developed with diaminobenzidine and counterstained with hematoxylin.

2.5. Hypertrophic Scars Induction in Rabbit Ears. White male New Zealand rabbits (4.3–4.5 kg) were used in four independent and extemporaneous experiments. Three to four wounds were created on the ventral side of each ear, down to the surface of the cartilage, using a 6 mm diameter punch biotome (Acuderm) as described [20]. For the surgical procedures, rabbits were anesthetized with intramuscular ketamine (60 mg/kg) and xylazine (5 mg/kg). In order to ensure an exuberant scarring, the perichondrium was carefully scrapped with the surgical blade. The wounds were made on each side of the midline, avoiding the central ear artery and the marginal ear veins. In three experiments, rabbits were randomly assigned to either GHRP-6 (400 μg/mL) treatment or 1% CMC placebo gel. The jelly solutions were administered using 1 mL sterile disposable syringes; 250 μL was applied to each wound, which for the group of GHRP-6 represented an actual dose of 100 μg per wound. Treatments were initiated immediately after surgery and continued thereafter until day 30, when most of the wounds had already completed reepithelialization.

The wounds were monitored and followed from day 14 until day 30 after wounding so as to detect the nodular firm consistency that precedes the clinical exuberance. The animals remained in observation for another 20 days after GHRP-6 administration had been completed. The incidence of firm, protruded nodules with nipple-like appearance arising in resurfaced wounds was registered weekly until day 50. After euthanasia (anesthesia overdose), the samples were collected in block, longitudinally bisected along the largest point of nodular growth. One hemisection was nitrogen frozen for additional studies and the other one was fixed in 10% neutral buffered formaldehyde and processed for histology. Five-micrometer sections were stained with H/E staining. Scar overgrowth was measured using the previously described scar elevation index (SEI) based on the cross-sectional scar area to the area of tissue excised to induce the wound [21]. Blinded researchers measured the sections using the ImageJ software package, version 1.46r.

2.6. Gene Expression Analysis. Total RNA was purified according to TRI Reagent standard procedure (Sigma, USA), following digestion with RQ1 DNase I (Promega, USA) to remove contaminating genomic DNA. Afterward, 500 ng of DNA-free RNA was reverse transcribed using Omniscript RT kit (Qiagen, Germany) with oligo-dT primer. The RT reaction was performed at 42°C for 60 min. PCR mixtures contained 1 μL cDNA, 1 μL of each primer (10 μM), and 12.5 μL 2x Taq MasterMix (Qiagen, Germany) in a final volume of 25 μL. Specific sense and antisense primers, annealing temperatures, and number of repeating cycles for both studies are referred to in Table 1. Amplifying conditions were performed as follows: a first step of 95°C for 5 minutes, thereafter repeating cycles comprised of 95°C for 30 seconds, specific annealing temperature for 30 seconds and 72°C for 30 seconds, and a final extension step of 5 minutes at 72°C. PCR bands (8 μL of PCR product plus 2 μL of gel loading buffer) were resolved on 1.5% (w/v) agarose gel electrophoresis and visualized under ultraviolet light subsequent to being stained with ethidium bromide. PCR products were quantified using the Kodak ID 3.6 software package (Kodak Inc, USA). Beta-2 microglobulin was used as a housekeeping gene for normalization.

2.7. Statistical Analysis. Statistical analyses were carried out using GraphPad Prism 6 for Windows, version 6.01. For clinical response, histomorphometric parameters, and gene expression data, normal distribution (Kolmogorov-Smirnov) and variance homogeneity (Brown-Forsythe) tests were performed. Once normality was demonstrated, differences between GHRP-6-treated and placebo-treated animals were determined using two-tailed unpaired Student’s t-test. For non-Gaussian distributed data, Mann-Whitney U test was performed. For analyzing closure kinetic differences between GHRP-6-treated and placebo-treated rabbits, the Log-rank (Mantel-Cox) test was used. Differences were noted after the first 24 hours (p = 0.016) following the initial administrations, which continued thereafter until the end of the experiment (p < 0.001).

At the histological analysis, and from a qualitative perspective, these wounds appeared less inflamed and with a higher degree of ECM organization, given by far less fibrin accumulation and thinner and horizontally distributed
| Symbol | Name                          | Gene Bank accession number | Sequence | Annealing temp. (°C) | Number of cycles | Product length (bp) |
|--------|-------------------------------|---------------------------|----------|----------------------|------------------|--------------------|
|        | **Rat oligonucleotides**      |                           |          |                      |                  |                    |
| Coll1  | Collagen, type I, alpha 1     | NM_053304                 | CCCCTCTGTGCCTCAGAAGAACT | 58                | 30               | 234                |
|        |                               |                           | GCCAGCTCGTGGGTCCCATGTAG |                   |                  |                    |
| Coll3  | Collagen, type III, alpha 1   | NM_032085                 | AAGAGGGGGAAATCTGGGTG    | 58                | 30               | 214                |
|        |                               |                           | CAGGATTGGCGATGCTGAACT   |                   |                  |                    |
| Tgfb1  | Transforming growth factor, beta 1 | NM_021578              | TGCCAGAACCCTCATTGCTG    | 70                | 35               | 700                |
|        |                               |                           | TCCACCCTGGGCTGCAGACC    |                   |                  |                    |
| Ctgf   | Connective tissue growth factor | NM_022266              | AGAGCTGGGTTGGTGTCCTCC   | 70                | 30               | 547                |
|        |                               |                           | GCCAGAAACACTCTCGTGG     |                   |                  |                    |
| Acta2  | Actin, alpha 2, smooth muscle, aorta | NM_031004          | GTGCCATCATATAGGACCTGC   | 68                | 35               | 601                |
|        |                               |                           | CATACTCGTGGTGTGACATGC   |                   |                  |                    |
| Tnf    | Tumor necrosis factor         | NM_012675                 | ATGGCATGGATCTCAAGAGCA   | 58                | 40               | 150                |
|        |                               |                           | TCTCCCTGTTGATAAGTGGCAA  |                   |                  |                    |
| Adam17 | ADAM metallopeptidase domain 17 | AJ012603             | GTGACATGAATGGGAATGTGA   | 55                | 40               | 172                |
|        |                               |                           | TGGAACAGGTCTGGAAGGAA    |                   |                  |                    |
| Cd36   | CD36 molecule (thrombospondin receptor) | NM_031561          | TGGCATATTGTTGCTGGAAT   | 62                | 35               | 217                |
|        |                               |                           | TGGCTTGGACAGATTGTTGACC  |                   |                  |                    |
| Vim    | Vimentin                      | NM_031140                 | GATTTCTCTGCTCTCCAAA     | 62                | 35               | 164                |
|        |                               |                           | GTACATGTTGTTGAGAAGTC    |                   |                  |                    |
| Des    | Desmin                        | NM_022531                 | AACATGACCAGGACACATCTT  | 62                | 35               | 181                |
|        |                               |                           | TGGGCTCTCTCACAATTTTGC   |                   |                  |                    |
| Pdgfb  | Platelet-derived growth factor beta polypeptide | NM_03524        | TTGCTCTCTTCTGCTGCTCCAA  | 62                | 35               | 303                |
|        |                               |                           | GCCGCCAGGAGATCTTTTCTGC  |                   |                  |                    |
| Fn1    | Fibronectin 1                 | NM_01943                  | GTGAGCCAGAGATCTTTTCTG   | 62                | 35               | 227                |
|        |                               |                           | GTGGTGCTTTTCTTGAGATTC   |                   |                  |                    |
| B2m    | Beta-2 microglobulin          | NM_12512                  | CATTGTCCAGGAGAGATGTTG   | 58                | 30               | 332                |
|        |                               |                           | CATTGTCCAGGAGAGATGTTG   |                   |                  |                    |
|        | **Rabbit oligonucleotides**   |                           |          |                      |                  |                    |
| TGFBI  | Transforming growth factor, beta 1 | XM_008249704     | TCAATTACCCGTCACCTCAGATGTG | 72                |                  | 229                |
|        |                               |                           | TGTGTAGATGTTGAGCCCGGTTC |                   |                  |                    |
| PDGFBI | Platelet-derived growth factor beta polypeptide | XM_00825709 | GGTGAGAAGATCAAGATTTGGTC | 62                | 40               | 231                |
|        |                               |                           | GTGTGCTTTAAGCTTGGTGGTGC |                   |                  |                    |
| CTGF   | Connective tissue growth factor | XM_008263527      | GGCCTAAGGTCTCGGGAGATGATG | 62                | 30               | 162                |
| Symbol | Name                                      | Gene Bank accession number | Sequence                        | Annealing temp. (°C) | Number of cycles | Product length (bp) |
|--------|-------------------------------------------|----------------------------|---------------------------------|----------------------|------------------|-------------------|
| MMP3   | Matrix metalloproteinase 3 (stromelysin 1, progelatinase) | NM_001082280              | Sense TCTCTTCITCAGCAGTGATG      | 58                   | 40               | 186               |
|        |                                           |                            | antisense TTCCTTATCAGAAATGGCAGCA |                      |                  |                   |
| COLIA1 | Collagen, type I, alpha 1                 | XM_008271783               | Sense CCTGGCGAGAGGAGGAAAGAG     | 62                   | 30               | 157               |
|        |                                           |                            | antisense CCTCACGTCCAGATTCCACCA |                      |                  |                   |
| IGFBP3 | Insulin-like growth factor binding protein 3 Peroxisome | NM_000598 (human)         | Sense TGCCGTAGAGAAATGGGAGAAG    | 72                   | 40               | 172               |
|        |                                           |                            | antisense GCCATACTTATCCACACACCA |                      |                  |                   |
| PPARG  | Proliferator-activated receptor gamma 1   | AY166780                   | Sense TGATGAAATAAGACGGGTCCT      | 62                   | 40               | 187               |
|        |                                           |                            | antisense CCACTGAAATGATGACGGCTA |                      |                  |                   |
| P4HB   | Prolyl 4-hydroxylase, beta polypeptide    | NM_001171047               | Sense ATGACCAAGTCAAAGCCCGAGT     | 62                   | 30               | 212               |
|        |                                           |                            | antisense GCGTGAACCTCCAGAAGACG   |                      |                  |                   |
| COL3A1 | Collagen, type III, alpha 1              | XM_002712333               | Sense AAAGAAAGCCCTGAAGCTGATG    | 62                   | 30               | 195               |
|        |                                           |                            | antisense GGCGGGAATGATGATGAGTT  |                      |                  |                   |
| B2M    | Beta-2 microglobulin                     | XM_002717921               | Sense GATCCCCATTTCACGTGCTAGCC   | 62                   | 30               | 195               |
Table 2: Impact of GHRP-6 topical administration on inflammation and fibroangiogenesis.

|                | Inflammatory cells | Active vessels | Dermal matrix reconstitution |
|----------------|--------------------|----------------|-----------------------------|
| GHRP-6         | 7.86 ± 2.41*       | 8.34 ± 3.02    | 1.9 ± 0.36*                 |
| Placebo        | 13.74 ± 3.91       | 8.38 ± 2.89    | 2.49 ± 0.38                 |

*p = 0.001. Two-tailed unpaired Student’s t-test.

Table 3: Effect of GHRP-6 in HTS prevention.

| Group    | Total # wounds | Hypertrophic phenotype | Normal phenotype | SEI   | SEI* |
|----------|----------------|------------------------|------------------|-------|------|
| GHRP-6   | 84             | 8 (9.5%)               | 76 (90.5%)       | 1.12 ± 0.11* | 1.63 ± 0.44 |
| Placebo  | 80             | 70 (87.5%)             | 10 (12.5%)       | 1.67 ± 0.15 | 1.66 ± 0.36 |

*SEI: scar elevation index measured in 8 nonresponsive wounds of the GHRP-6 treated group. *p = 0.001; two-tailed unpaired Student’s t-test.

Figure 1: GHRP-6 accelerated wound closure. Differences in wounded area reduction appeared since the first 24 hours of post-injury. GHRP-6-induced contraction remained stable until hour 96, when the animals were terminated. Two-way ANOVA (*p = 0.016, ***p < 0.001).

Collagen bundles. Vessels were also aligned with the collagen fibers. Thus, the treatment not only reduced the wound area but also appeared to be associated with differences in the quality of the ECM as the inflammatory infiltrate. Figure 2(a) is representative of the GHRP-6 effect on the inflammatory response, illustrating the reduction of infiltrated cells as compared to placebo-treated wounds (Figure 2(b)).

Since CD36 is implicated in angiogenesis regulation, special attention was addressed to the population of neovessels as to their general morphology. By routine staining, we ascertained that GHRP-6 treatment did not reduce the number of vessels, which also exhibited normal structure, organization, and distribution. Furthermore, CD31 expression was detected in all these vascular structures suggesting mature angiogenesis. Conclusively, GHRP-6 administration did not hinder wound angiogenesis in any respect (Figure 3(a)), as compared to placebo-treated wounds (Figure 3(b)). These histological findings support the scoring on the ECM maturation and the quantification of inflammatory cells across the wounds (Table 2).

Following the preliminary histological data, suggesting a reduction of wound inflammation and a far more organized ECM, we addressed the gene expression study toward inflammatory and profibrogenic markers. We primarily examined Cd36 expression following topical GHRP-6 application and found that peptide reduced its receptor expression (*p = 0.004) (Figure 4). Furthermore, the treatment significantly reduced Adam17 expression (*p = 0.0306) and approached to significantly reduce Tnf (*p = 0.07), which may partially contribute to explaining the substantial reduction of infiltrated inflammatory cells within the wound bed (Figure 4).

Furthermore, the most potent profibrogenic growth factors: Tgfb1, Pdgfb, and Ctgf also appeared significantly underexpressed in the GHRP-6-treated wounds (all *p < 0.05) (Figure 4). In line with this, we observed a significant reduction in the expression levels of Colla1 and Col3a1 (Figure 4, both *p < 0.01). Concomitantly, we addressed the attention to filamentous and contractile proteins associated with fibroblasts and other differentiated mesenchyme-derived cells. Acta2 appeared close to a significant reduction (*p = 0.06), whereas Des, Vim, and Fn transcriptional expression appeared significantly reduced (all *p < 0.05), as compared to placebo-treated wounds.

3.2. GHRP-6 Prevented the Onset of HTS in Rabbits. According to pilot studies, our group determined that 400 μg/mL represented an optimal dose level by reducing inflammation, promoting collagen fibers alignment, while aborting the onset of HTS in rabbit ears. A lower dose (200 μg/mL) did not prevent the exuberant phenotype whereas a higher dose (800 μg/mL) delayed reepithelialization in rats and rabbits (data not shown).

Placebo-treated wounds appeared hypertrophied and proved a firm consistency by day 17 onward. For the three experiments, day 30 following injury established a clear definition on the wounds evolution. The most remarkable effect of GHRP-6 intervention can be ascribed to HTS prevention. As shown in Table 3, GHRP-6 administration aborted the debut of HTS in 90.5% of the treated wounds. These wounds...
Figure 2: GHRP-6-mediated response to inflammation. Images are representative of (a) wounds topically treated with vehicle (1% CMC); (b) wounds topically treated with GHRP-6. GHRP-6 treatment reduced the inflammatory infiltration of mononuclear basophilic round cells. In contrast, CMC-treated wounds exhibit a physiologically normal infiltration, which matches the biological stage of the wound. 5 μm section, H/E, 20x magnification.

Figure 3: Impact of GHRP-6 treatment on wound angiogenesis. Anti-CD31 immunolabeling for mature endothelial cells. Images are representative of (a) vehicle (1% CMC)-treated wounds; (b) GHRP-6-treated wounds. No histological differences were detected between the groups in relation to the number of neovessels, their structure, distribution, organization, or CD31 positivity.

were also negative to palpation. On the contrary, 87.5% of the wounds receiving the jelly CMC solution evolved to HTS with nipple-like, reddish appearance and a firm consistency nodule at palpation (Figures 5(a) and 5(b)).

The qualitative microscopic analysis of the GHRP-6 responsive wounds indicated that the peptide seems to primarily reduce both local hypercellularity associated with the cartilage perichondrium cells and the resulting ECM accumulation (Figures 6(a) and 6(b)). Accordingly, their SEI (1.12 ± 0.11) appeared largely different (p = 0.001) as compared to the placebo samples group (1.62 ± 0.15). It is noteworthy, however, that those GHRP-6 nonresponsive wounds (n = 8) that evolved to HTS exhibited similar microscopic appearance (not shown) and SEI values as compared to placebo control wounds (Table 3).

RT-PCR experiments shed light on the molecular mechanisms by which GHRP-6 appeared to modulate the fibrotic response. Among the genes studied (Table 1), GHRP-6 proved to significantly reduce TGFβ1 and CTGF (p < 0.05) expression, with no effect on PDGFB gene expression. An unexpected finding was that MMP3 appeared significantly reduced in the GHRP-6-treated wounds (p = 0.02). Most meaningfully is that PPARG expression became significantly elevated with GHRP-6 treatment (p = 0.016), as compared to placebo-treated wounds (Figure 7).

4. Discussion

The evidence derived from these experiments supports the notion that CD36 is an active and approachable receptor to modulate the healing process. Here we have observed that CD36 occupation by GHRP-6 attenuates wound inflammation, accelerates wound closure, and above all improved wound’s esthetic outcome by impacting ECM proteins accumulation. To our knowledge these findings are unprecedented for GHRP-6 within the context of cutaneous healing.

The experiment in rats, based on clean full-thickness controlled wounds, indicated that GHRP-6 pharmacodynamics has likely involved attenuation of immunoinflammatory mediators, their effector cells, and the reduction of fibrosis-inducing cytokines. The concerted action of these two elemental mechanisms may have theoretically translated
Figure 4: Influence of GHRP-6 on the expression of different gene families. RT-PCR experiments demonstrate the GHRP-6-induced reduction of the expression of its own receptor (Cd36). Concurrently, the peptide significantly reduced proinflammatory and profibrogenic cytokines. It is likely that the attenuation of these fibrogenic growth factors accounted for a reduction of extracellular matrix proteins and mesenchymal cells cytoskeleton proteins. Unpaired $t$-test (*$p<0.05$, **$p<0.01$, and ***$p<0.001$).

Figure 5: Topical GHRP-6 improved the macroscopic aspect of the wounds. (a) Representative wounds that evolved to hypertrophic scars (HTS). (b) Representative image of the effect of GHRP-6 administration.

into a particular modulation of fibroblasts response to injury, leading to precocious closure with a reduced scarring. Outstandingly, the mechanisms underlying this pattern of healing do not appear to interfere with the angiogenic repopulation nor with the reepithelialization process.

The response of these wounds reminds us of the pattern of healing described for MG53 protein (a membrane repair machinery member), so that the treatment facilitated wound healing along with a reduced scarring in rodent models. This antiscar effect was explained by interfering with TGF-$\beta$-dependent activation of myofibroblasts differentiation and reduction of ECM proteins accumulation [22]. Similarly, antiscarring healing properties are described for plants’ principles that downregulate the expression of fibrogenic-related molecules such as TGF-$\beta$1 and the downstream events, leading to fibrosis and scar formation [23]. In addition to a direct action of GHRP-6 on TGFBI gene expression, we deem that the reduction of inflammatory effectors could have also contributed to enhancing the healing process and to reducing fibrosis. In an animal model of liver ischemia/reperfusion, we previously demonstrated that GHRP-6 prevented internal organs parenchymal activation and the onset of a systemic inflammatory response syndrome by downregulating proinflammatory cytokines [24]. Subsequent studies have
Figure 6: Microscopic aspect of the rabbits’ ears wounds. (a) Representative image of “nipple” in which, above the cartilage and the perichondrium, there is a prominent accumulation of extracellular matrix. (b) Representative image of the effect induced by the GHRP-6 intervention. Note the reduction of extracellular matrix accumulation within the injured area. The “flattening” aspect is indicated by the solid line arrow. The dotted arrows indicate that the elevation within the center of the scar is similar to the adjacent intact skin. Images suggest that GHRP-6 reduced the local hypercellularity associated with the cartilage cells response. H/E 10x magnification.

Figure 7: Potential bases of GHRP-6-mediated antifibrotic effect. Among these four genes significantly modulated by GHRP-6 of biological relevance within this realm are TGFB1 reduction and PPARG increase. Mann-Whitney U test. *P < 0.05.

demonstrated the ability of different GHRPs to ameliorate local and systemic inflammatory processes in a variety of experimental scenarios by suppressing the activation of NF-κB, the consequent expression of proinflammatory cytokines, and acting as chemokine receptor antagonist [25–27]. Differentiation to myofibroblasts, collagen fibrillogenesis, and matrix accumulation are controlled by opposing forces: proinflammatory and profibrogenic, that require a fine tuning to ensure a proper esthetic healing and effective mechanical properties of the ECM [28, 29]. The overall interpretation of the data from (i) the rate of closure, (ii) microscopic appearance of the collagen fibrils alignment/organization, (iii) impact of the treatment on the transcriptional expression of cytoskeleton filamentous proteins (smooth muscle α-actin (α-SMA), desmin, and vimentin) supports the hypothesis that, in this context, GHRP-6 has shifted the balance toward “a more regenerative” rather than a reparative phenotype.

Aside from the limitations of this work to fully elucidate the underlying mechanism by which GHRP-6 mediated the refinement of the wounds fibrogenesis in the rats experiment, an important contribution is the unprecedented evidence that the peptide reduced the onset of HTS in the rabbit’s ear model. This represents an extension of the GHRP-6 antifibrotic potential demonstrated years ago by our group in an animal model of liver fibrosis [7]. Nevertheless, and in contrast to the liver fibrosis data, we have no evidence that GHRP-6 is able to revert the consolidated HTS following repeated experimental attempts. Thus, the reproducible findings regarding GHRP-6-mediated HTS prevention are based on the immediate and consecutive administration of the molecule once the injury is induced.

The mechanisms supporting the GHRP-6-mediated HTS prevention may be related to a potential modulation of the fibrogenic response, especially by TGF-β1 transcriptional deactivation and its downstream effector CTGF, as has been previously described [30]. Nevertheless, we have not elucidated the pathways involved in the GHRP-6-mediated TGFB1 gene expression reduction. Under these circumstances, we have reproducibly observed [7] that GHRP-6 increases PPARG expression which may have counteracted TGF-β1-associated fibrogenic input. The fact that CD36 occupation by GHRP-6 upregulated PPARG gene expression is noteworthy in this context and represents an additional pharmacologic property for this peptide. Although the molecular pathways underlying the antifibrotic effects of PPARY remain elusive, an antagonistic relationship is proposed between PPARY and TGF-β1 signaling in fibrosis. For more than a decade ago, PPARY has been reputed as a fibrosis-response regulating
factor and its activation represents an innovative pathway to control fibrotic diseases [31,32].

Taking into account the broad spectrum of TGF-β1 physiology in the fibroblasts/myofibroblasts differentiation events [33], we deem that the reduction of the local scar cellularity and perichondrial matrix accumulation in those animals receiving GHRP-6 could be attributable to TGFBI transcriptional and functional switch-off. Since the predominant microscopic aspect of the GHRP-6-treated wounds was characterized by meagre cartilage scars, slimmer perichondrium membranes, and far less active cells, we hypothesize that the peptide somehow attenuates the perichondrial activation response to the trauma and/or a possible mesenchyme-tomesenchyme redifferentiation process, thus lessening the surge of fibroblast and myofibroblasts. In line with this notion, we had documented that GHRP6 prevented hepatic stellate cells activation by reducing CD68, α-SMA, and vimentin local expressions. All these events could be primarily presided by the GHRP-6-related reduction of TGFBI and CTGF expression in both parenchymal and nonparenchymal cells [7].

5. Conclusions

The evidence described here presupposes the existence of a GHRP-6/CD36-mediated anti-inflammatory and antifibrotic loop that appears to improve wound closure and aesthetic. The activity of this binomium may represent a novel and attractive avenue toward the timely prevention of dismal cutaneous processes such as keloids and HTS.

Competing Interests

The authors declare that they have no competing interests.

References

[1] N. Jumper, R. Paus, and A. Bayat, “Functional histopathology of keloid disease,” Histology and Histopathology, vol. 30, no. 9, pp. 1033–1057, 2015.

[2] G. P. Sidgwick and A. Bayat, “Extracellular matrix molecules implicated in hypertrophic and keloid scarring,” Journal of the European Academy of Dermatology and Venereology, vol. 26, no. 2, pp. 141–152, 2012.

[3] Q. Ye, S.-J. Wang, J.-Y. Chen, K. Rahman, H.-L. Xin, and H. Zhang, “Medicinal plants for the treatment of hypertrophic scars,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 101340, 15 pages, 2015.

[4] W. S. Jang, J. Park, K. H. Yoo et al., “Branch-shaped cutaneous hypopigmentation and atrophy after intralesional triamcinolone injection,” Annals of Dermatology, vol. 23, no. 1, pp. 111–114, 2011.

[5] A. Aslian, A. Darougheh, and F. Shariati, “New combination of triamcinolone, 5-fluouracil, and pulsed-dye laser for treatment of keloid and hypertrophic scars,” Dermatologic Surgery, vol. 32, no. 7, pp. 907–915, 2006.

[6] N. N. Goyal and M. H. Gold, “A novel triple medicine combination injection for the resolution of keloids and hypertrophic scars,” Journal of Clinical and Aesthetic Dermatology, vol. 7, no. 11, pp. 31–34, 2014.

[7] J. Berlanga-Acosta, D. Vázquez-Blomquist, D. Cibrín et al., “Growth Hormone Releasing Peptide 6 (GHRP6) reduces liver fibrosis in CCl4 chronically intoxicated rats,” Biotecnologia Aplicada, vol. 29, no. 2, pp. 60–72, 2012.

[8] D. Cibrín, J. Berlanga, L. Guevara et al., “Cardiac and extracardiac cytoprotective effects of GHRP6 peptide,” Biotecnologia Aplicada, vol. 25, no. 3, pp. 276–281, 2008.

[9] J. Berlanga, D. Cibrín, L. Guevara et al., “Growth-hormone-releasing peptide 6 (GHRP6) prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction,” Clinical Science, vol. 112, no. 3–4, pp. 241–250, 2007.

[10] A. Delgado-Rubín De Célix, J. A. Chowen, J. Argente, and L. M. Frago, “Growth hormone releasing peptide-6 acts as a survival factor in glutamate-induced excitotoxicity,” Journal of Neurochemistry, vol. 99, no. 3, pp. 839–849, 2006.

[11] Y.-T. Shen, J. J. Lynch, R. J. Hargreaves, and R. J. Gould, “A growth hormone secretagogue prevents-ischemic-induced mortality independently of the growth hormone pathway in dogs with chronic dilated cardiomyopathy,” Journal of Pharmacology and Experimental Therapeutics, vol. 306, no. 2, pp. 815–820, 2003.

[12] A. Demers, N. McNicoll, M. Febbraio et al., “Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study,” Biochemical Journal, vol. 382, no. 2, pp. 417–424, 2004.

[13] S. Cho, “CD36 as a therapeutic target for endothelial dysfunction in stroke,” Current Pharmaceutical Design, vol. 18, no. 25, pp. 3721–3730, 2012.

[14] J. E. Nor, L. Dipietro, J. E. Murphy-Ullrich, R. O. Hynes, J. Lawler, and P. J. Polverini, “Activation of latent TGF-beta by thrombospondin-1 is a major component of wound repair,” Oral Biosciences & Medicine, vol. 2, no. 2, pp. 153–161, 2005.

[15] P. R. Lawler and J. Lawler, “Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2,” Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 5, Article ID a006627, 2012.

[16] S. O. Canapp Jr., J. P. Farese, G. S. Schultz et al., “The effect of topical tripeptide-copper complex on healing of ischemic open wounds,” Veterinary Surgery, vol. 32, no. 6, pp. 515–523, 2003.

[17] J. Berlanga, J. Lodos, and V. P. Labarta, “The effect of epidermal growth factor treatment schedule on the healing of full-thickness wounds in pigs,” Biotecnologia Aplicada, vol. 14, no. 3, pp. 163–168, 1997.

[18] J. Berlanga, E. Moreira, L. C. Pérez, E. Boix, T. González, and P. López-Saura, “Wound healing promotion in rats is EGF dose dependent,” Biotecnologia Aplicada, vol. 13, no. 3, pp. 181–185, 1996.

[19] J. R. Privratsky and P. J. Newman, “PECAM-1: regulator of endothelial junctional integrity,” Cell and Tissue Research, vol. 355, no. 3, pp. 607–619, 2014.

[20] D. E. Morris, L. Wu, L. L. Zhao et al., “Acute and chronic animal models for excessive dermal scarring: quantitative studies,” Plastic and Reconstructive Surgery, vol. 100, no. 3, pp. 674–681, 1997.

[21] S. Jia, Y. Zhao, M. Law, R. Galiano, and T. A. Mustoe, “The effects of collagenase ointment on the prevention of hypertrophic scarring in a rabbit ear scarring model: a pilot study,” Wounds, vol. 23, no. 6, pp. 160–165, 2011.

[22] H. Li, P. Duann, P.-H. Lin et al., “Modulation of wound healing and scar formation by MG53 protein-mediated cell membrane repair,” Journal of Biological Chemistry, vol. 290, no. 40, pp. 24592–24603, 2015.
[23] X. Bai, T. He, J. Liu et al., “Loureirin B inhibits fibroblast proliferation and extracellular matrix deposition in hypertrophic scar via TGF-β/Smad pathway,” Experimental Dermatology, vol. 24, no. 5, pp. 355–360, 2015.

[24] D. Cibrián, H. Ajamieh, J. Berlanga et al., “Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure,” Clinical Science, vol. 110, no. 5, pp. 563–573, 2006.

[25] M. Granado, A. I. Martin, M. Lopez-Menduina, A. Lopez-Calderon, and M. A. Villanua, “GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia,” American Journal of Physiology–Endocrinology and Metabolism, vol. 294, no. 1, pp. E131–E141, 2007.

[26] K. Patel, Y. D. Dixit, J. H. Lee et al., “The GHS-R blocker D-[Lys3] GHRP-6 serves as CCR5 Chemokine receptor antagonist,” International Journal of Medical Sciences, vol. 9, no. 1, pp. 51–58, 2012.

[27] G. Li, J. Li, Q. Zhou, X. Song, H. Liang, and L. Huang, “Growth hormone releasing peptide-2, a ghrelin agonist, attenuates lipopolysaccharide-induced acute lung injury in rats,” Tohoku Journal of Experimental Medicine, vol. 222, no. 1, pp. 7–13, 2010.

[28] B. S. Herrera, A. Kantarci, A. Zarrough, H. Hasturk, K. P. Leung, and T. E. Van Dyke, “LXA4 actions direct fibroblast function and wound closure,” Biochemical and Biophysical Research Communications, vol. 464, no. 4, pp. 1072–1077, 2015.

[29] H.-M. Zhou, J. Wang, C. Elliott, W. Wen, D. W. Hamilton, and S. J. Conway, “Spatiotemporal expression of peristin during skin development and incisional wound healing: lessons for human fibrotic scar formation,” Journal of Cell Communication and Signaling, vol. 4, no. 2, pp. 99–107, 2010.

[30] M. Sisco, Z. B. Kryger, K. D. O’Shaughnessy et al., “Antisense inhibition of connective tissue growth factor (CTGF/CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivo,” Wound Repair and Regeneration, vol. 16, no. 5, pp. 661–673, 2008.

[31] A. T. Dantas, M. C. Pereira, M. J. B. de Melo Rego et al., “The role of PPAR gamma in systemic sclerosis,” PPAR Research, vol. 2015, Article ID 124624, 12 pages, 2015.

[32] S. M. Ferrari, A. Antonelli, A. Di Domenicantonio, A. Manfredi, C. Ferri, and P. Fallahi, “Modulatory effects of peroxisome proliferator-activated receptor-γ on CXCR3 chemokines,” Recent Patents on Inflammation and Allergy Drug Discovery, vol. 8, no. 2, pp. 132–138, 2014.

[33] R. Vivar, C. Humeres, C. Muñoz et al., “FoxO1 mediates TGF-betadependent cardiac myofibroblast differentiation,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, vol. 1863, no. 1, pp. 128–138, 2016.